BR112022003698A2 - Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica - Google Patents
Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêuticaInfo
- Publication number
- BR112022003698A2 BR112022003698A2 BR112022003698A BR112022003698A BR112022003698A2 BR 112022003698 A2 BR112022003698 A2 BR 112022003698A2 BR 112022003698 A BR112022003698 A BR 112022003698A BR 112022003698 A BR112022003698 A BR 112022003698A BR 112022003698 A2 BR112022003698 A2 BR 112022003698A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- treating
- pharmaceutical composition
- virus infection
- infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica. a presente divulgação refere-se a composições farmacêuticas que compreendem um anticorpo que neutraliza a infecção pelo vírus da hepatite b (hbv). além disso, a presente divulgação refere-se ao uso das composições farmacêuticas no tratamento da infecção pelo hbv.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962893742P | 2019-08-29 | 2019-08-29 | |
PCT/US2020/048649 WO2021042000A1 (en) | 2019-08-29 | 2020-08-28 | Antibody compositions and methods for treating hepatitis b virus infection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003698A2 true BR112022003698A2 (pt) | 2022-05-24 |
Family
ID=72473989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003698A BR112022003698A2 (pt) | 2019-08-29 | 2020-08-28 | Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220380441A1 (pt) |
EP (1) | EP4021578A1 (pt) |
JP (1) | JP2022545920A (pt) |
KR (1) | KR20220063188A (pt) |
CN (1) | CN114630680A (pt) |
AU (1) | AU2020336980A1 (pt) |
BR (1) | BR112022003698A2 (pt) |
CA (1) | CA3152511A1 (pt) |
IL (1) | IL290923A (pt) |
MX (1) | MX2022002231A (pt) |
WO (1) | WO2021042000A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202245838A (zh) * | 2021-01-26 | 2022-12-01 | 美商維爾生物科技股份有限公司 | 用於治療b型肝炎病毒感染的組成物及方法 |
WO2023230439A1 (en) * | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
ATE303445T1 (de) | 1999-10-04 | 2005-09-15 | Medicago Inc | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
US20090252729A1 (en) | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
BRPI0914092B1 (pt) | 2008-10-22 | 2021-08-31 | Institute For Research In Biomedicine | Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo |
EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
JP2016505843A (ja) | 2012-12-19 | 2016-02-25 | アンプリミューン, インコーポレイテッド | B7−h4特異的抗体、並びにその組成物及び使用方法 |
TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗-b7-h4抗體及免疫結合物 |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
JP7115856B2 (ja) | 2015-02-19 | 2022-08-09 | コンピュジェン リミテッド | 抗pvrig抗体及び使用方法 |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
PE20201339A1 (es) * | 2017-12-19 | 2020-11-25 | Univ Rockefeller | Variantes de dominio de fc de igg humana con funcion efectora mejorada |
EP4292659A3 (en) * | 2018-12-19 | 2024-03-20 | Humabs Biomed SA | Antibodies that neutralize hepatitis b virus and uses thereof |
SG11202106489RA (en) * | 2018-12-20 | 2021-07-29 | Vir Biotechnology Inc | Combination hbv therapy |
-
2020
- 2020-08-28 BR BR112022003698A patent/BR112022003698A2/pt unknown
- 2020-08-28 MX MX2022002231A patent/MX2022002231A/es unknown
- 2020-08-28 EP EP20771699.4A patent/EP4021578A1/en active Pending
- 2020-08-28 JP JP2022513208A patent/JP2022545920A/ja active Pending
- 2020-08-28 KR KR1020227010266A patent/KR20220063188A/ko unknown
- 2020-08-28 US US17/637,605 patent/US20220380441A1/en active Pending
- 2020-08-28 CA CA3152511A patent/CA3152511A1/en active Pending
- 2020-08-28 WO PCT/US2020/048649 patent/WO2021042000A1/en active Application Filing
- 2020-08-28 CN CN202080075610.1A patent/CN114630680A/zh active Pending
- 2020-08-28 AU AU2020336980A patent/AU2020336980A1/en active Pending
-
2022
- 2022-02-27 IL IL290923A patent/IL290923A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021042000A1 (en) | 2021-03-04 |
KR20220063188A (ko) | 2022-05-17 |
IL290923A (en) | 2022-04-01 |
US20220380441A1 (en) | 2022-12-01 |
EP4021578A1 (en) | 2022-07-06 |
CN114630680A (zh) | 2022-06-14 |
MX2022002231A (es) | 2022-03-22 |
AU2020336980A1 (en) | 2022-03-24 |
JP2022545920A (ja) | 2022-11-01 |
CA3152511A1 (en) | 2021-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
UY37581A (es) | Compuestos para el tratamiento de la infección por virus de la hepatitis b | |
PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
MX2018009917A (es) | Vacuna contra el virus del zika. | |
BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
BR112022003698A2 (pt) | Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica | |
EA202091114A1 (ru) | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) | |
CR20160520A (es) | Oligómeros y conjugados de oligómeros | |
BR112014010295A2 (pt) | métodos e composições para o tratamento de vírus de hepatite c | |
AR072302A1 (es) | Pestivirus atenuados. composicion inmunogenica. metodo. | |
EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
EA202191736A1 (ru) | Комбинированная терапия hbv | |
MX2021006997A (es) | Arilmetilureas y heteroarilmetilureas sustituidas, análogos de las mismas y métodos para utilizar las mismas. | |
MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
MX2022013251A (es) | Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento de vhb. | |
PH12020500176A1 (en) | A composition for treating and/or preventing hepatitis b virus infection and the use thereof | |
BR112021019845A2 (pt) | Composições de vírus inativado e formulações de vacina contra zika | |
AR117191A1 (es) | Composiciones inmunogénicas | |
MX2021013698A (es) | Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb). | |
BR112021026506A2 (pt) | Método para fabricar anamicina liofilizada, método para produzir liofilizado de anamicina pré-lipossômico, composição de liofilizado de anamicina pré-lipossômico e método para tratar câncer | |
BR112022023135A2 (pt) | Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas | |
MX2021006654A (es) | Uso de extracto de cocculus hirsutus para tratar dengue. | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с |